Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Comerica Bank

Comerica Bank lessened its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 75.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,803 shares of the medical research company's stock after selling 5,454 shares during the period. Comerica Bank's holdings in Exact Sciences were worth $101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of EXAS. Perigon Wealth Management LLC lifted its position in shares of Exact Sciences by 3.2% during the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company's stock valued at $474,000 after acquiring an additional 264 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Exact Sciences by 2.0% during the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock valued at $763,000 after acquiring an additional 269 shares during the period. Daiwa Securities Group Inc. lifted its position in shares of Exact Sciences by 2.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company's stock valued at $812,000 after acquiring an additional 300 shares during the period. Curi RMB Capital LLC lifted its position in shares of Exact Sciences by 1.7% during the 4th quarter. Curi RMB Capital LLC now owns 24,896 shares of the medical research company's stock valued at $1,399,000 after acquiring an additional 428 shares during the period. Finally, Patten & Patten Inc. TN lifted its position in shares of Exact Sciences by 1.8% during the 4th quarter. Patten & Patten Inc. TN now owns 26,153 shares of the medical research company's stock valued at $1,470,000 after acquiring an additional 460 shares during the period. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Trading Up 0.8%

Shares of NASDAQ EXAS traded up $0.47 during trading on Friday, hitting $56.95. 2,057,391 shares of the company traded hands, compared to its average volume of 2,560,261. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a 50-day moving average price of $47.58 and a 200-day moving average price of $51.84. The firm has a market capitalization of $10.74 billion, a P/E ratio of -10.22 and a beta of 0.92. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. During the same period in the prior year, the company earned ($0.60) EPS. The firm's revenue was up 10.9% on a year-over-year basis. On average, equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Analysts Set New Price Targets

EXAS has been the subject of a number of research reports. Barclays lifted their price target on shares of Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a research report on Friday, May 2nd. Piper Sandler cut their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Mizuho began coverage on Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective for the company. Guggenheim restated a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a research report on Friday, April 11th. Finally, Royal Bank of Canada lifted their price objective on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $70.90.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.